Factor VIII replacement is still the standard of care in haemophilia A

被引：95

作者：

Aledort, Louis ^{[1
]}

Mannucci, Pier Mannuccio ^{[2
]}

Schramm, Wolfgang ^{[3
]}

Tarantino, Michael ^{[4
,5
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Hematol Oncol, New York, NY 10029 USA

[2] IRCCS Fdn Ca Granda Maggiore Policlin Hosp, Sci Direct, Via Pace 9, I-20122 Milan, Italy

[3] Univ Hosp Munich, Dept Transfus Med & Haemostasis, Munich, Germany

[4] Univ Illinois, Coll Med, Peoria, IL 61656 USA

[5] Bleeding & Clotting Disorders Inst, Peoria, IL USA

来源：

BLOOD TRANSFUSION | 2019年 / 17卷 / 06期

关键词：

factor VIII; haemophilia A; prophylaxis; standard of care; half-life; RECOMBINANT FACTOR-VIII; FC FUSION PROTEIN; EXTENDED-HALF-LIFE; BAY; 94-9027; EMICIZUMAB PROPHYLAXIS; BISPECIFIC ANTIBODY; IMMUNE TOLERANCE; FULL-LENGTH; ON-DEMAND; SAFETY;

D O I：

10.2450/2019.0211-19

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management of major surgery, and long-term data on the impact of emicizumab on joint health, FVIII inhibitor development and thrombotic risk are awaited. Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals.

引用

页码：479 / 486

页数：8

共 69 条

[21] Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial [J].

Gruppo, Ralph ;

Lopez-Fernandez, Maria-Fernanda ;

Wynn, Tung T. ;

Engl, Werner ;

Sharkhawy, Marlies ;

Tangada, Srilatha .

HAEMOPHILIA, 2019, 25 (05) :773-781

[22] First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A [J].

Hampton, K. ;

Chowdary, P. ;

Dunkley, S. ;

Ehrenforth, S. ;

Jacobsen, L. ;

Neff, A. ;

Santagostino, E. ;

Sathar, J. ;

Takedani, H. ;

Takemoto, C. M. ;

Negrier, C. .

HAEMOPHILIA, 2017, 23 (05) :689-696

[23] The principal results of the International Immune Tolerance Study: a randomized dose comparison [J].

Hay, Charles R. M. ;

DiMichele, Donna M. .

BLOOD, 2012, 119 (06) :1335-1344

[24]

Hoots WK, 2007, EMERGENCY CARE ISSUE, V43

[25] Using pharmacokinetics to individualize hemophilia therapy [J].

Iorio, Alfonso .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, :595-604

[26] PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers [J].

Ivens, I. A. ;

Baumann, A. ;

McDonald, T. A. ;

Humphries, T. J. ;

Michaels, L. A. ;

Mathew, P. .

HAEMOPHILIA, 2013, 19 (01) :11-20

[27]

JIMENEZYUSTE V, 2017, BLOOD S1, V130

[28] A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model [J].

Kitazawa, Takehisa ;

Igawa, Tomoyuki ;

Sampei, Zenjiro ;

Muto, Atsushi ;

Kojima, Tetsuo ;

Soeda, Tetsuhiro ;

Yoshihashi, Kazutaka ;

Okuyama-Nishida, Yukiko ;

Saito, Hiroyuki ;

Tsunoda, Hiroyuki ;

Suzuki, Tsukasa ;

Adachi, Hideki ;

Miyazaki, Taro ;

Ishii, Shinya ;

Kamata-Sakurai, Mika ;

Iida, Takeo ;

Harada, Aya ;

Esaki, Keiko ;

Funaki, Miho ;

Moriyama, Chifumi ;

Tanaka, Eriko ;

Kikuchi, Yasufumi ;

Wakabayashi, Tetsuya ;

Wada, Manabu ;

Goto, Masaaki ;

Toyoda, Takeshi ;

Ueyama, Atsunori ;

Suzuki, Sachiyo ;

Haraya, Kenta ;

Tachibana, Tatsuhiko ;

Kawabe, Yoshiki ;

Shima, Midori ;

Yoshioka, Akira ;

Hattori, Kunihiro .

NATURE MEDICINE, 2012, 18 (10) :1570-U177

[29] Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A [J].

Konkle, Barbara A. ;

Stasyshyn, Oleksandra ;

Chowdary, Pratima ;

Bevan, David H. ;

Mant, Tim ;

Shima, Midori ;

Engl, Werner ;

Dyck-Jones, Jacqueline ;

Fuerlinger, Monika ;

Patrone, Lisa ;

Ewenstein, Bruce ;

Abbuehl, Brigitt .

BLOOD, 2015, 126 (09) :1078-1085

[30] Evaluating the safety of emicizumab in patients with hemophilia A [J].

Langer, Arielle L. ;

Etra, Aaron ;

Aledort, Louis .

EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) :1233-1237

← 1 2 3 4 5 6 7 →